Published online June 1, 2007
PEDIATRICS Vol. 119 No. 6 June 2007, pp. 1076-1082 (doi:10.1542/peds.2006-3176)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chiu, S. S.
Right arrow Articles by Lau, Y. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chiu, S. S.
Right arrow Articles by Lau, Y. L.
Related Collections
Right arrow Infectious Disease & Immunity

ARTICLE

Immunogenicity and Safety of Intradermal Influenza Immunization at a Reduced Dose in Healthy Children

Susan S. Chiu, MD, FAAPa, J.S. Malik Peiris, DPhil, FRCPath, FRSb,c, Kwok H. Chan, PhDb, Wilfred Hing Sang Wong, MMedSca and Yu Lung Lau, MDa

a Department of Pediatrics and Adolescent Medicine
b Department of Microbiology, University of Hong Kong, Hong Kong, China
c Pasteur Research Centre, Hong Kong University, Hong Kong, China

OBJECTIVES. We conducted this study to test the hypothesis that intradermal influenza vaccination at one fifth of a standard dose elicits comparable immunogenicity to full-dose intramuscular vaccination in children.

PATIENTS AND METHODS. We conducted a randomized, open-label study in 112 healthy children aged 3 to <18 years to compare the immunogenicity and safety of intradermal vaccination at one fifth of a dose with standard intramuscular vaccination. Analyses of hemagglutination inhibition antibody titers to each antigen in each group included geometric mean titers before and 21 days after vaccination, fold increase in geometric mean titers after vaccination, seroprotection rate, and seroconversion rate.

RESULTS. The mean age of the subjects was 10.11 ± 4.04 years in the intradermal vaccination group and 10.57 ± 3.91 years in the intramuscular group. Intradermal vaccination was safe. Induration and mild erythema at the injection site were reported at 25% and 57%, respectively, in the intradermal group. Fold increase of geometric mean titers against influenza A/Caledonia was robust in both groups (11.1-fold and 12.9-fold increase in the intramuscular and intradermal groups, respectively), whereas that for B/Shandong was more modest (4.3–4.4). Both approaches elicited very high geometric mean titers against influenza A/Panama: 1360.5 and 893.9 for the intramuscular and intradermal groups, respectively, but because the prevaccination antibody titers were high, the fold increase of geometric mean titers was only 4.5 and 2.6, respectively.

CONCLUSION. The immunogenicity of one fifth of a dose of influenza vaccine delivered by the intradermal route is comparable to the standard-dose intramuscular vaccination in children as young as 3 years of age.

Key Words: influenza vaccine • children • intradermal • reduced dosage

Abbreviations: H1N1—A/New Caledonia/20/99 • H3N2— A/California/7/2004 • HAI—hemagglutination inhibition • RDE—receptor-destroying enzyme • GMT—geometric mean titer

Accepted Jan 30, 2007.